SCHEMBL29699267

SCHEMBL29699267

CNc1ncc2cc(Br)c(C)nc2n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAF1 P04049 4/20 0.38
▸ KRAS P01116 3/20 0.38
▸ BRAF P15056 3/20 0.38
▸ KDR P35968 3/20 0.38
▸ MAPK13 O15264 1/20 0.38
▸ ABL1 P00519 1/20 0.38
▸ FYN P06241 1/20 0.38
▸ ARAF P10398 1/20 0.38
▸ SRC P12931 1/20 0.38
▸ EPHA2 P29317 1/20 0.38
▸ CSK P41240 1/20 0.38
▸ MAPK8 P45983 1/20 0.38
▸ MAPK9 P45984 1/20 0.38
▸ IRAK1 P51617 1/20 0.38
▸ MAPK12 P53778 1/20 0.38
▸ MAPK10 P53779 1/20 0.38
▸ EPHB4 P54760 1/20 0.38
▸ MAP2K5 Q13163 1/20 0.38
▸ MAP3K1 Q13233 1/20 0.38
▸ MAPK11 Q15759 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15263527 1.00 RAF1 (0.38) RAF1KRASBRAFKDRMAPK13
SCHEMBL22612761 0.89 RAF1 (0.34) RAF1KRASBRAFKDRMAPK13
SCHEMBL27103100 0.83 LRRK2 (0.36) RAF1KRASBRAFKDRMAPK13
SCHEMBL24457858 0.81 LRRK2 (0.35) RAF1KRASBRAFKDRMAPK13
SCHEMBL24457853 0.81 FGFR1 (0.40) SRCEGFRFGFR1SIK1SIK2
SCHEMBL22612769 0.81 FGFR1 (0.32) FGFR1
SCHEMBL27103117 0.79 MAPK8 (0.38) MAPK8EGFRFGFR1LRRK2
SCHEMBL22625609 0.78 KRAS (0.31) RAF1KRASBRAFKDRMAPK13
SCHEMBL22612825 0.78 ULK1 (0.34) RAF1KRASBRAFKDRMAPK13
SCHEMBL29990890 0.77 IDH1 (0.36) KDRFYNMAPK8MAPK9HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4247795-A1 GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF Deciphera Pharmaceuticals, LLC (US) 2023-09-27 — — EP disclosed
US-20220274934-A1 GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2022-09-01 — — US disclosed
WO-2022109001-A1 GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC (US) 2022-05-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220274934-A1 GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF EIF2AK4, GCN1, EEF2K RAF1 388/4885KRAS 414/4885BRAF 295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback